⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3963502 | 0.98 | — | — | |
| Pyrrole SCHEMBL18797670 | 0.89 | — | — | |
| SCHEMBL460674 | 0.85 | — | — | |
| SCHEMBL5583489 | 0.81 | — | — | |
| Piperazine SCHEMBL7414302 | 0.73 | — | — | |
| SCHEMBL8902925 | 0.71 | HTT (0.32) | — | |
| SCHEMBL28669823 | 0.68 | EPHX1 (0.31) | — | |
| SCHEMBL5155602 | 0.68 | BCAT2 (0.45) | — | |
| SCHEMBL27205294 | 0.67 | — | — | |
| SCHEMBL16238310 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022046682-A1 | BROMODOMAIN AND EXTRA TERMINAL DOMAIN (BET) INHIBITOR COMPOSITIONS AND METHODS THEREOF FOR USE AS ANTI-AGING AGENTS | MDI BIOLOGICAL LABORATORY (US) | 2022-03-03 | — | — | WO | claimed |
| WO-2009046004-A1 | CARBOXAMIDE GABAA ALPHA2 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-09 | — | — | WO | claimed |
| US-20240246977-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHOD OF USE | BEONE MEDICINES I GMBH (CH) | 2024-07-25 | — | — | US | disclosed |
| EP-4359403-A1 | (R) -GLUTARIMIDE CRBN LIGANDS AND METHODS OF USE | BeiGene Switzerland GmbH (CH) | 2024-05-01 | — | — | EP | disclosed |
| US-20240043439-A1 | COMPOUNDS AS C5AR INHIBITORS | KIRA PHARMACEUTICALS (SUZHOU) LTD. (CN) | 2024-02-08 | — | — | US | disclosed |
| CN-116981675-A | Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitors to E3 ligase ligands and methods of use | 百济神州有限公司 | 2023-10-31 | — | — | CN | disclosed |
| WO-2022268052-A9 | (R) -GLUTARIMIDE CRBN LIGANDS AND METHODS OF USE | BEIGENE, LTD. (KY) | 2023-08-17 | — | — | WO | disclosed |
| EP-3654968-B1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-3313828-B1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| WO-2022268052-A1 | (R) -GLUTARIMIDE CRBN LIGANDS AND METHODS OF USE | BEIGENE, LTD. (KY) | 2022-12-29 | — | — | WO | disclosed |
| CN-109790170-B | GABA (A) receptor modulators and methods of controlling airway hyperresponsiveness and inflammation in asthma | UWM研究基金会有限公司 | 2022-08-02 | — | — | CN | disclosed |
| EP-2997029-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | Glaxosmithkline LLC (US) | 2016-03-23 | — | — | EP | disclosed |
| WO-2014186313-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2014-11-20 | — | — | WO | disclosed |
| WO-2009046004-A1 | CARBOXAMIDE GABAA ALPHA2 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-09 | — | — | WO | disclosed |
| EP-1727551-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN | Arrow Therapeutics Limited (GB) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005089771-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
| US-5739129-A | AGONIST ACTIVITY | GLAXO WELLCOME INC. (US) | 1998-04-14 | — | — | US | disclosed |
| EP-0790999-A1 | OXAZOLYL- AND THIAZOLYLIMIDAZO-BENZO- AND THIENODIAZEPINES AND THEIR USE AS MEDICAMENTS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996015129-A1 | OXAZOLYL- AND THIAZOLYLIMIDAZO-BENZO- AND THIENODIAZEPINES AND THEIR USE AS MEDICAMENTS | F. HOFFMANN-LA ROCHE AG (CH) | 1996-05-23 | — | — | WO | disclosed |
| WO-1993025554-A1 | BENZODIAZEPINES AND COMPOSITIONS FOR TREATING ANXIETY AND PANIC DISORDERS, AND IDIOPATHIC AND PSYCHOMOTOR EPILEPSY | HOFFMANN-LA ROCHE INC. (US) | 1993-12-23 | — | — | WO | disclosed |